Healthcare [ 5/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 15, 23 | -0.11
Increased by
+31.25%
|
-0.14
Increased by
+153.06%
|
May 12, 23 | -0.11
Increased by
+31.25%
|
-0.14
Increased by
+153.06%
|
Mar 30, 23 | -0.11
Increased by
+15.38%
|
-0.15
Increased by
+177.78%
|
Nov 14, 22 | -0.12
Increased by
+57.14%
|
-0.18
Increased by
+185.19%
|
Aug 16, 22 | -0.16
Increased by
+27.27%
|
-0.14
Decreased by
-102.04%
|
Aug 15, 22 | -0.16
Increased by
+36.00%
|
-0.14
Decreased by
-102.04%
|
May 16, 22 | -0.13
Increased by
+45.83%
|
-0.17
Increased by
+138.41%
|
Mar 28, 22 | -0.28
Decreased by
-16.67%
|
-0.21
Decreased by
-158.73%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Mar 31, 23 | 0.00
Decreased by
N/A%
|
-2.89 M
Decreased by
-4.87%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 22 | 0.00
Decreased by
N/A%
|
-2.87 M
Increased by
+52.37%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-3.03 M
Increased by
+29.80%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-3.86 M
Increased by
+12.98%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-2.76 M
Increased by
+42.97%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-6.02 M
Decreased by
-73.50%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-4.32 M
Decreased by
-29.44%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-4.44 M
Decreased by
-145.21%
|
Decreased by
N/A%
Decreased by
N/A%
|
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.